Thursday, October 01, 2020 2:54:32 PM
"Said, who died in 2013, “was an enormous proponent of VIP and was looking for a clinical applications for most of his life after the discovery,” according to a former colleague, Nicholas Hill, MD, of Tufts University.
That eventually led to aviptadil. It was initially thought to have application in pulmonary hypertension and acute respiratory distress syndrome (ARDS). But after eight patients showed a “miraculous response,” said Hill, subsequent trials were unable to show any significant benefit. That was in the early 2000s."
"Miraculous response" sound familiar with the same drug lol?
Again I think this is a good product, but now is the time to take profit, get back in at a lower position / price and lets see what happens.
CBD Life Sciences Inc. (CBDL) Launches High-Demand Mushroom Gummy Line for Targeted Wellness Needs, Tapping into a Booming $20 Billion Market • CBDL • Oct 31, 2024 8:00 AM
Nerds On Site Announces Q1 Growth and New Initiatives for the Remainder of 2024 • NOSUF • Oct 31, 2024 7:01 AM
Innovation Beverage Group Receives Largest Shipment of its Top-Selling Bitters to Date in the U.S.-Ready to Meet Growing Demand from Expanding Distribution Network • IBG • Oct 30, 2024 12:22 PM
Element79 Gold Corp to Update Investors on the Emerging Growth Conference on October 31, 2024 • ELMGF • Oct 30, 2024 9:08 AM
CBD Life Sciences Inc. (CBDL) Announces Grand View Research Report Findings on High - Growth CBD Equine Market, Aiming to Drive Unprecedented Shareholder Value • CBDL • Oct 29, 2024 10:19 AM
Integrated Ventures Announces Partnership And Lease Agreement with Driptide Wellness - Leading Health and Wellness Provider. • INTV • Oct 29, 2024 8:45 AM